Patient-Focused Treatment Decisions in
the Management of Type 2 Diabetes: Expert Perspectives on the
Evolving Role of SGLT2 Inhibitors in Cardiovascular and Renal
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2020 Fall
Managed Care Forum. If you participated in the live session, you are
not eligible for continuing education credits from this archive.
This activity is valid from February 1, 2021 to March 1, 2022
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by
educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
The American Diabetes Association (ADA) estimates that more than
30.3 million people in the United States, or 9.4 percent of the
population, have diabetes, and that one in three Americans born in
2019 will develop diabetes sometime during their lifetime. About
90-95% of adults who have diabetes have type 2 Diabetes Mellitus
(DM). According to the Centers for Disease Control (CDC),
uncontrolled type 2 DM doubles a person’s risk for death, and on
average individuals with type 2 DM lose 10-15 years of life. The
management of type 2 DM remains a major challenge as many patients
continue to struggle with achieving therapeutic goals, including
control of A1C level, blood pressure, cholesterol, and weight.
Fortunately, recent advances in treatments in Type 2 Diabetes
management have given healthcare professionals the ability to shrink
this clinical practice gap.
While the prevalence of diabetes continues to rise, a new generation
of treatments has become available in the past few years. Continuing
education is needed to educate health care professionals about these
agents for treatment of T2DM that are effective in lowering A1C
levels. Treatments have become available that allow the
individualization of T2DM management. There have been many questions
in member surveys and past program evaluations about the best
practices in regards to the role of combination therapies comprised
of SGLT-2 inhibitors in the management of type 2 diabetes.
Additionally, new clinical trial data has become available for
antidiabetic therapies that have shown improved outcomes for
reducing macrovascular risk factors associated with T2DM, including
hypertension and heart failure. It is critical that medical
directors, clinicians, nurses and other healthcare professionals are
educated about this new data and how it will affect the type 2
diabetes treatment paradigm.
Upon completion of this
activity, participants will be able to:
Describe the pathophysiologic
relationships between T2DM and cardiovascular disease (CVD),
heart failure (HF), and chronic kidney disease (CKD), including
implications for antihyperglycemic treatment
Examine the role of anti-diabetic
therapy, in particular the use of SGLT2 inhibitors, in a
risk-based intervention strategy that targets glucose control
and cardiovascular and renal risk factors
Discuss the mechanistic profiles,
evidence for clinical benefits, and safety concerns associated
with SGLT2 inhibitors as treatment options for patients with
Compare the designs and results of
large-scale cardiovascular and renal outcomes trials with SGLT2
inhibitors for T2DM
Assess the managed care
considerations of SGLT2 inhibitors by exploring where these
agents fit into the evolving T2DM management paradigm
||Silvio Inzucchi, MD
Professor of Medicine, Fellowship Program Director,
Section of Endocrinology
Yale School of Medicine
Clinical Chief, Endocrinology
Medical Director, Yale Diabetes Center
Yale-New Haven Hospital
Inzucchi serves on an advisory board for AstraZeneca,
Boehringer Ingelheim, Merck, Novo Nordisk, and Sanofi/Lexicon.
He has served as a consultant for Abbott, Esperion, and
VTV Therapeutics. His presentation has been peer
reviewed for any bias.
MD has no real or perceived financial relationships to
Jeremy Williams has no real or perceived financial
relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived
financial relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue